SanBio Co Ltd (JP:4592)
:4592
Want to see JP:4592 full AI Analyst Report?
4592 Stock Chart & Stats
¥2230.00
¥19.00(2.53%)
At close: 4:00 PM EST
¥2230.00
¥19.00(2.53%)
Day’s Range― - ―
52-Week Range¥1,173.00 - ¥3,990.00
Previous CloseN/A
Volume765.40K
Average Volume (3M)2.08M
Market Cap
¥98.74B
Enterprise Value¥97.60B
Total Cash (Recent Filing)¥2.74B
Total Debt (Recent Filing)¥1.36B
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Jun 15, 2026EPS Estimate
-6.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-50.61
Shares Outstanding78,058,880
10 Day Avg. Volume2,869,570
30 Day Avg. Volume2,080,090
Financial Highlights & Ratios
PEG Ratio-1.38
Price to Book (P/B)9.94
Price to Sales (P/S)0.00
P/FCF Ratio-35.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,750.00Price Target Upside-21.52% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-55.39
Revenue Forecast (FY)¥2.05B
Bulls Say, Bears Say
Bulls Say
Proprietary Cell-therapy PlatformSanBio’s proprietary cell-based platform and focus on neurological/serious diseases represent a durable business model advantage. Specialized cell therapy R&D creates high technical barriers, long development cycles and potential for differentiated therapeutics and licensing/partnering optionality if clinical milestones are met.
Stronger Equity And Manageable LeverageThe recent equity increase and expanded assets improve solvency metrics on paper, and multi-year debt-to-equity in the ~0.21–0.24 range (outside the 2022 spike) provides a clearer buffer versus insolvency. This structural balance-sheet improvement supports runway and strategic optionality for development-stage investments.
Improving Cash Burn And Narrowing LossesCash-burn and net-loss trends have improved from peak 2023 extremes, indicating better cost discipline or program prioritization. A sustained reduction in outflows, if maintained, lengthens runway and reduces near-term financing pressure, making execution on clinical milestones more feasible over the medium term.
Bears Say
No Revenue / Pre-commercial StatusSanBio remains entirely pre-commercial with zero reported revenue, meaning future success depends on uncertain clinical outcomes and eventual market uptake. Absence of operating revenue makes the firm highly dependent on capital markets and milestone-based partnerships for sustained operations and growth.
Persistent Negative Free Cash FlowConsistent, substantial negative operating and free cash flow shows the business consumes cash to fund R&D with no internal generation. This structural cash burn necessitates repeated external financing, elevating dilution risk and limiting the company’s ability to self-fund late-stage trials or commercialization without partners.
Financing Risk And Leverage VolatilityHistoric leverage volatility and recent increases in debt demonstrate reliance on external financing and sensitivity to funding conditions. For a pre-revenue biotech, this pattern implies persistent refinancing or dilution risk and shows solvency can worsen quickly if financing terms tighten or clinical progress stalls.
SanBio Co News
4592 FAQ
What was SanBio Co Ltd’s price range in the past 12 months?
SanBio Co Ltd lowest stock price was ¥1173.00 and its highest was ¥3990.00 in the past 12 months.
What is SanBio Co Ltd’s market cap?
SanBio Co Ltd’s market cap is ¥98.74B.
When is SanBio Co Ltd’s upcoming earnings report date?
SanBio Co Ltd’s upcoming earnings report date is Jun 15, 2026 which is in 6 days.
How were SanBio Co Ltd’s earnings last quarter?
SanBio Co Ltd released its earnings results on Mar 17, 2026. The company reported -¥14.8 earnings per share for the quarter, beating the consensus estimate of -¥20.693 by ¥5.893.
Is SanBio Co Ltd overvalued?
According to Wall Street analysts SanBio Co Ltd’s price is currently Overvalued.
Does SanBio Co Ltd pay dividends?
SanBio Co Ltd does not currently pay dividends.
What is SanBio Co Ltd’s EPS estimate?
SanBio Co Ltd’s EPS estimate is -6.19.
How many shares outstanding does SanBio Co Ltd have?
SanBio Co Ltd has 78,058,880 shares outstanding.
What happened to SanBio Co Ltd’s price movement after its last earnings report?
SanBio Co Ltd reported an EPS of -¥14.8 in its last earnings report, beating expectations of -¥20.693. Following the earnings report the stock price went down -1.733%.
Which hedge fund is a major shareholder of SanBio Co Ltd?
Currently, no hedge funds are holding shares in JP:4592
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SanBio Co Ltd
SanBio Company Limited is dedicated to the creation, production, and sale of regenerative cell therapies, primarily concentrated on disorders of the central nervous system. A central component of their portfolio is SB623, a treatment that has completed Phase 2 clinical trials in both the United States and Japan for traumatic brain injury. Beyond this, their comprehensive research pipeline explores the broader potential of SB623 for conditions such as ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, and Alzheimer's disease. The company's development efforts also encompass other innovative treatments: SB618 for peripheral nerve damage, SB308 for muscular dystrophy, MSC1 for cancer, and MSC2 for inflammatory diseases and optic neuritis. Founded in 2001, SanBio maintains its corporate headquarters in Tokyo, Japan.
4592 Company Deck
4592 Earnings Call
Q4 2026
0:00 / 0:00
4592 Stock 12 Month Forecast
Average Price Target
¥1,750.00
▼(-21.52% Downside)
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---